Bromocriptine Citrate Composition for Solubility and Shelf Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bromocriptine mesylate exhibits poor water solubility and is susceptible to water and heat degradation, limiting its stability and absorption across biological membranes, necessitating higher dosages for effective treatment of metabolic disorders.
Innovation Solution
Formulating bromocriptine as bromocriptine citrate, which enhances its aqueous solubility and stability, allowing for improved absorption and reduced dosage requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bromocriptine is formulated as mesylate salt, then it can be manufactured and administered, but it exhibits poor water solubility and is susceptible to water and heat degradation
Solution Approach 1:
The patent changes the chemical form of bromocriptine from mesylate salt to citrate salt, altering the molecular parameters to improve both water solubility and stability. This parameter change transforms the drug's physical-chemical properties without changing its core pharmacological activity, resolving the contradiction between solubility and stability.
Solution Approach 2:
The invention creates a composite salt form (bromocriptine citrate) that combines the properties of both bromocriptine base and citric acid. This composite material exhibits superior water solubility and stability compared to the original mesylate salt, effectively resolving the technical contradiction through material composition optimization.
2Quantity of substance
If bromocriptine mesylate is used, then dosage can be adjusted, but higher dosages are required due to poor absorption
Solution Approach 1:
By changing the salt form from mesylate to citrate, the patent modifies the absorption parameters of bromocriptine. The citrate form exhibits improved bioavailability and absorption characteristics, allowing for reduced dosage while maintaining or enhancing therapeutic effect, thus resolving the contradiction between quantity required and absorption efficiency.
3Duration of action of stationary object
If bromocriptine mesylate is formulated, then it can be stored, but shelf life is limited due to degradation
Solution Approach 1:
The patent changes the chemical stability parameters by forming bromocriptine citrate instead of mesylate salt. This parameter change confers enhanced resistance to water and heat degradation, directly extending the shelf life and storage stability of the pharmaceutical product, thereby resolving the contradiction between storage duration and stability.
Data Source
AI summary
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.